Trial · NCT03887676
Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)
NCT03887676, Phase 2, Completed, Holland Bloorview Kids Rehabilitation Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA). Trials, record NCT03887676. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03887676
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)
- NCT number
- NCT03887676
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 90 participants, actual
- Lead sponsor
- Holland Bloorview Kids Rehabilitation Hospital
- Conditions
- Autism Spectrum Disorder
- Interventions
- Arbaclofen, Placebo
- First posted
- 2019-03-25
- Last updated
- 2025-07-16
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Social Domain | 16 weeks | To examine the effect of arbaclofen vs. placebo social function |
| Secondary | Clinical Global Impressions - Impression Scale - Improvement (CGI-I) | 16 weeks | To examine the effect of arbaclofen vs. placebo on measures of global function |
| Secondary | Aberrant Behavior Checklist (ABC) - Social Withdrawal Subscale | 16 weeks | To examine the effect of arbaclofen vs. placebo on social withdrawal |
| Secondary | Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) - Communication Domain | 16 weeks | To examine the effect of arbaclofen vs. placebo on communication |
| Secondary | Safety Monitoring Uniform Report Form (SMURF) | 16 weeks | To examine the safety and tolerability of arbaclofen in children and adolescents with ASD |
| Secondary | Clinical Global Impressions - Impression Scale - Global (CGI-I-Global) | 16 weeks | To examine the safety and tolerability of arbaclofen in children and adolescents with ASD |
| Secondary | Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) | 16 weeks | To examine the safety and tolerability of arbaclofen in children and adolescents with ASD |
| Secondary | Suicidality assessment using the Columbia-Suicide Severity Rating Scale (C-SSRS) | 16 weeks | To examine the safety and tolerability of arbaclofen in children and adolescents with ASD |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37811711 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03887676
GET https://conductscience.org/api/trials/v1/NCT03887676/registered